Practical guidance on the use of sacubitril/valsartan for heart failure
AbstractSacubitril/valsartan is a first-in-class angiotensin receptor-neprilysin inhibitor (ARNI) that has been recommended in clinical practice guidelines to reduce morbidity and mortality in patients with chronic, symptomatic heart failure (HF) with reduced ejection fraction (HFrEF). This review provides an overview of ARNI therapy, proposes strategies to improve the implementation of sacubitril/valsartan in clinical practice, and provides clinicians with evidence-based, practical guidance on the use of sacubitril/valsartan in patients with HFrEF. Despite evidence demonstrating the benefits of ARNI therapy over standard ...
Source: Heart Failure Reviews - December 18, 2018 Category: Cardiology Source Type: research

Sacubitril/Valsartan in Adult Congenital Heart Disease Patients With Chronic Heart Failure − A Single Centre Case Series and Call for an International Registry
An improvement in life expectancy in patients suffering from adult congenital heart disease (ACHD) has corresponded with a rise in heart failure incidence within this group. An area that has not been addressed in ACHD heart failure guidelines has been the use of combined inhibition of angiotensin receptor-neprolysin pathways. This case series sought to demonstrate tolerability and 6-month outcome measures of sacubitril/valsartan use in ACHD patients with a severely impaired systemic ventricle. (Source: Heart, Lung and Circulation)
Source: Heart, Lung and Circulation - December 17, 2018 Category: Cardiology Authors: V. Appadurai, J. Thoreau, T. Malpas, M. Nicolae Tags: Original Article Source Type: research

The efficacy and safety of valsartan and a combination of valsartan and hydrochlorothiazide in the treatment of patients with mild to moderate arterial hypertension: a subgroup analysis of the effect of valsartan and its combination with ….
CONCLUSIONS: Valsartan and valsartan/HCTZ improve arterial stiffness in patients with mild to moderate hypertension. PMID: 29192957 [PubMed - indexed for MEDLINE] (Source: Kardiologia Polska)
Source: Kardiologia Polska - December 12, 2018 Category: Cardiology Authors: Accetto R, Widimsky J, Vincelj J, Sirenko Y, Yevgenyevna IC, Barbic Zagar B Tags: Kardiol Pol Source Type: research

Initial clinical experience with the first drug (sacubitril/valsartan) in a new class - angiotensin receptor neprilysin inhibitors in patients with heart failure with reduced left ventricular ejection fraction in Poland.
CONCLUSIONS: It was demonstrated that the use of sacubitril/valsartan in outpatients with HFrEF is safe and is associated with a significant clinical improvement. PMID: 29192956 [PubMed - indexed for MEDLINE] (Source: Kardiologia Polska)
Source: Kardiologia Polska - December 12, 2018 Category: Cardiology Authors: Kałużna-Oleksy M, Kolasa J, Migaj J, Pawlak A, Lelonek M, Nessler J, Straburzyńska-Migaj E Tags: Kardiol Pol Source Type: research

Is sacubitril/valsartan safe for treatment of hypertension at any age?
No abstract available (Source: Journal of Cardiovascular Medicine)
Source: Journal of Cardiovascular Medicine - December 12, 2018 Category: Cardiology Tags: Letter to the editor Source Type: research

Contemporary Management of Heart Failure in the Elderly
AbstractThe foundation of the treatment of heart failure with reduced ejection fraction is a number of pharmacotherapies shown to reduce morbidity and mortality in large randomised multinational clinical trials. These include angiotensin converting enzyme inhibitors, angiotensin receptor blockers, beta-blockers, mineralocorticoid receptor antagonists, and more recently, a combined angiotensin receptor blocker neprilysin inhibitor, sacubitril/valsartan. In select cases, digoxin, ivabradine and hydralazine with isosorbide dinitrate have a role to play in the treatment of heart failure with reduced ejection fraction. On this ...
Source: Drugs and Aging - December 11, 2018 Category: Geriatrics Source Type: research

Exploitation of localized surface plasmon resonance of silver/gold nanoparticles for the fluorescence quantification of angiotensin II receptor antagonists in their tablets and bio-samples
New J. Chem., 2019, Advance Article DOI: 10.1039/C8NJ05218B, PaperN. A. Alarfaj, S. A. Altamimi, M. F. El-Tohamy, A. M. Almahri The present study suggested six different fluorimetric systems for the determination of three angiotensin II receptor antagonists, candesartan cilexetil (CDC), valsartan (VAL) and telmisartan (TEL) in their bulk and pharmaceutical dosage forms. To cite this article before page numbers are assigned, use the DOI form of citation above. The content of this RSS Feed (c) The Royal Society of Chemistry (Source: RSC - New J. Chem. latest articles)
Source: RSC - New J. Chem. latest articles - December 10, 2018 Category: Chemistry Authors: N. A. Alarfaj Source Type: research

Effects of sacubitril/valsartan on neprilysin targets and the metabolism of natriuretic peptides in chronic heart failure: a mechanistic clinical study
ConclusionSacubitril/valsartan rapidly and strongly reduced sNEP activity, leading to an increase in levels of NEP substrates. These data suggest a pleiotropic favourable impact of sacubitril/valsartan on the metabolism of HF patients with ANP rather than BNP as major effectors amongst natriuretic peptides. (Source: European Journal of Heart Failure)
Source: European Journal of Heart Failure - December 6, 2018 Category: Cardiology Authors: H élène Nougué, Théo Pezel, François Picard, Malha Sadoune, Mattia Arrigo, Florence Beauvais, Jean‐Marie Launay, Alain Cohen‐Solal, Nicolas Vodovar, Damien Logeart Tags: Research Article Source Type: research

Switching from ramipril to sacubitril/valsartan favorably alters electrocardiographic indices of ventricular repolarization in heart failure with reduced ejection fraction.
Authors: Okutucu S, Sabanoglu C, Yetis Sayin B, Aksoy H, Bursa N, Oto A Abstract BACKGROUND: Angiotensin receptor neprilysin inhibitor (ARNI, sacubitril/valsartan) reduces sudden death in heart failure with reduced ejection fraction (HFrEF). Corrected QT (QTc), T-wave peak to T-wave end interval (Tp-e) and Tp-e/QTc are electrocardiographic indices of ventricular repolarization heterogeneity. We aimed to assess the effects of switching from ramipril to ARNI on electrocardiographic indices of ventricular repolarization. METHODS: A total of 48 patients with HFrEF (mean age: 63.3 ± 11.7 years; ...
Source: Acta Cardiologica - December 5, 2018 Category: Cardiology Tags: Acta Cardiol Source Type: research

Outcome postponement as a potential patient centred measure of therapeutic benefit: examples in cardiovascular medicine.
CONCLUSIONS: Using outcome postponement as an additional measure of treatment effect is likely to be more easily understood than hazard ratio or RRR by both patients and physicians and could help when evaluating drugs. PMID: 30513258 [PubMed - as supplied by publisher] (Source: Acta Cardiologica)
Source: Acta Cardiologica - December 5, 2018 Category: Cardiology Tags: Acta Cardiol Source Type: research

Exploitation of localized surface plasmon resonance of silver/gold nanoparticles for the fluorescence quantification of angiotensin II receptor antagonists in their tablets and bio-samples
New J. Chem., 2018, Advance Article DOI: 10.1039/C8NJ05218B, PaperN. A. Alarfaj, S. A. Altamimi, M. F. El-Tohamy, A. M. Almahri The present study suggested six different fluorimetric systems for the determination of three angiotensin II receptor antagonists, candesartan cilexetil (CDC), valsartan (VAL) and telmisartan (TEL) in their bulk and pharmaceutical dosage forms. To cite this article before page numbers are assigned, use the DOI form of citation above. The content of this RSS Feed (c) The Royal Society of Chemistry (Source: RSC - New J. Chem. latest articles)
Source: RSC - New J. Chem. latest articles - December 4, 2018 Category: Chemistry Authors: N. A. Alarfaj Source Type: research

More valsartan products recalled
A further product recall for heart and blood pressure drug valsartan has  been issued by the Medicines and Healthcare products Regulatory Agency. (Source: The Pharmaceutical Journal)
Source: The Pharmaceutical Journal - December 3, 2018 Category: Drugs & Pharmacology Source Type: research

YAP activation promotes the transdifferentiation of cardiac fibroblasts to myofibroblasts in matrix remodeling of dilated cardiomyopathy.
Authors: Jin B, Zhu J, Shi HM, Wen ZC, Wu BW Abstract Yes-associated protein (YAP) is an important regulator of cellular proliferation and transdifferentiation. However, little is known about the mechanisms underlying myofibroblast transdifferentiation in dilated cardiomyopathy (DCM). We investigated the role of YAP in the pathological process of cardiac matrix remodeling. A classic model of DCM was established in BALB/c mice by immunization with porcine cardiac myosin. Cardiac fibroblasts were isolated from neonatal Sprague-Dawley rats by density gradient centrifugation. The expression levels of α-smooth mus...
Source: Brazilian Journal of Medical and Biological Research - November 30, 2018 Category: Research Tags: Braz J Med Biol Res Source Type: research

Effects of sacubitril/valsartan on functional status and exercise capacity in real-world patients.
Authors: Lau CW, Martens P, Lambeets S, Dupont M, Mullens W Abstract BACKGROUND: Sacubitril/valsartan significantly reduced heart failure(HF) hospitalisations and mortality in the PARADIGM-HF-trial. However real-world data on symptomatic and functional improvement are lacking. METHODS: Between December 2016 and January 2018, we retrospectively collected baseline and follow-up data including New York Heart Association (NYHA)-functional class and Cardio-pulmonary exercise data(CPET) in all HF-patients receiving sacubitril/valsartan. Additionally, in patients with an implantable electric cardiovascular device (IEC...
Source: Acta Cardiologica - November 28, 2018 Category: Cardiology Tags: Acta Cardiol Source Type: research

Safety and efficacy of sacubitril─valsartan in acute heart failure
Safety and efficacy of sacubitril─valsartan in acute heart failure, Published online: 27 November 2018; doi:10.1038/s41569-018-0134-5Safety and efficacy of sacubitril─valsartan in acute heart failure (Source: Nature Reviews Cardiology)
Source: Nature Reviews Cardiology - November 27, 2018 Category: Cardiology Authors: Alexandra Le Bras Source Type: research

Treatment of hypertension to prevent atrial fibrillation.
Abstract Atrial fibrillation (AF) and hypertension (HT) are expected to rapidly rise worldwide in the next few years. Important improvements in AF therapy are hampered by pro-arrhythmic and bleeding risks of current medications. Prevention of AF is an important matter as it will not only prevent the disease but also medications side effects, and it is likely to be cost effective. HT is a major contributor to AF. As a modifiable risk factor, its treatment might reduce new-onset AF, and recurrent AF after cardioversion or ablation as well. We review here the effect of HT treatment to prevent AF. Renin-angiotensin sy...
Source: Current Pharmaceutical Design - November 26, 2018 Category: Drugs & Pharmacology Authors: De Becker B, De Borne Philippe V Tags: Curr Pharm Des Source Type: research

Multiresidue analytical method for the determination of 41 multiclass organic pollutants in mussel and fish tissues and biofluids by liquid chromatography coupled to tandem mass spectrometry.
Abstract In this work, the full optimisation and validation procedure to analyse a wide set of emerging organic contaminants in biotissues (mussel and fish muscle, liver, gills and brain) and biofluids (fish plasma and bile) is described. The target families include artificial sweeteners, industrial products, hormones, pharmaceutical and personal care products, pesticides and phytoestrogens. Different clean-up strategies (hydrophilic-lipophilic-balanced (HLB) solid-phase extraction, Florisil solid-phase extraction and liquid-liquid extraction followed by HLB solid-phase extraction and microextraction based on poly...
Source: Analytical and Bioanalytical Chemistry - November 26, 2018 Category: Chemistry Authors: Mijangos L, Ziarrusta H, Zabaleta I, Usobiaga A, Olivares M, Zuloaga O, Etxebarria N, Prieto A Tags: Anal Bioanal Chem Source Type: research

Nebivolol/Valsartan: A Novel Antihypertensive Fixed-Dose Combination Tablet.
CONCLUSION: Nebivolol/valsartan combination may offer a benefit to patients with an indication for both classes who desire to decrease pill burden. Although BP lowering was statistically significant in comparison to the individual components as monotherapy, the combination does not offer clinically significant benefits that would elevate its place in HTN management. PMID: 30449127 [PubMed - as supplied by publisher] (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - November 18, 2018 Category: Drugs & Pharmacology Authors: Battise D, Boland CL, Nuzum DS Tags: Ann Pharmacother Source Type: research

Photo-electro-Fenton process applied to the degradation of valsartan: Effect of parameters, identification of degradation routes and mineralization in combination with a biological system
Publication date: Available online 15 November 2018Source: Journal of Environmental Chemical EngineeringAuthor(s): Diana Martínez-Pachón, María Ibáñez, Félix Hernández, Ricardo A. Torres-Palma, Alejandro Moncayo-LassoAbstractIn this work, the oxidation of the antihypertensive drug valsartan by the Electro-Fenton (EF) and Photo-Electro-Fenton (PEF) processes was studied using a Ti/IrO2 doped with SnO2 as anode, and a carbon felt air diffusion electrode as cathode. Initially, the influence of variables such as supporting electrolyte type, current density, and pH on EF and/or P...
Source: Journal of Environmental Chemical Engineering - November 16, 2018 Category: Chemistry Source Type: research

Pharmacokinetics of liposomal curcumin (Lipocurc ™) infusion: effect of co-medication in cancer patients and comparison with healthy individuals
ConclusionEither co-medications or health status, or both, can impact the pharmacokinetics of curcumin infusion (as Lipocurc ™) in cancer patients. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - November 14, 2018 Category: Cancer & Oncology Source Type: research

NDMA Impurity in Valsartan and other Pharmaceutical Products: Analytical Methods for the Determination of N-Nitrosamines
Discussion on NDMA as API impurity is extended to other drugs since then. Already several years before scientific literature reported NDMA as impurity of several other drugs, thus underlining the apparent risk. At present none of the pharmacopoeias tests for NDMA and only very limited publications of methods for its determination in pharmaceuticals are published so far. This review summarizes aspects for the analyses of nitrosoamines (NAs) with special focus on NDMA and discusses their potential applicability for drug analyses. The majority of recent publications utilize GC-MS or GC-MS/MS due to its high selectivity and lo...
Source: Journal of Pharmaceutical and Biomedical Analysis - November 12, 2018 Category: Drugs & Pharmacology Source Type: research

Improving access to novel heart failure agents through a defined multidisciplinary pathway
ConclusionsDespite considerable therapeutic advances and emerging device therapies, heart failure remains a tremendous medical and socioeconomic problem. There is a compelling need for improved clinical treatment for this complex population, and novel heart failure medication therapies has shown tremendous promise in improving health outcomes and quality of life in these patients. By defining a multidisciplinary pathway that has allowed access to these new, promising heart failure agents, our institution has allowed access to medication therapies that typically were not being filled and/or prescribed at other clinics and h...
Source: Heart and Lung: The Journal of Acute and Critical Care - November 11, 2018 Category: Respiratory Medicine Source Type: research

Long-term clinical outcomes of valsartan in patients with a systemic right ventricle: Follow-up of a multicenter randomized controlled trial
In the VAL-SERVE (Valsartan in Systemic Right Ventricle) trial, three-year valsartan treatment improved systemic ventricular function only in symptomatic patients with congenitally or with an atrial switch corrected transposition of the great arteries. The aim of the current study was to investigate the longer-term clinical outcomes after valsartan treatment. (Source: International Journal of Cardiology)
Source: International Journal of Cardiology - November 10, 2018 Category: Cardiology Authors: Alexandra C. van Dissel, Michiel M. Winter, Teun van der Bom, Hubert W. Vliegen, Arie P.J. van Dijk, Petronella G. Pieper, Gert-Jan T. Sieswerda, Jolien W. Roos-Hesselink, Aeilko H. Zwinderman, Barbara J.M. Mulder, Berto J. Bouma Tags: Short communication Source Type: research

Approaches of validation of a 2-week combined repeated oral dose toxicity study with plasma micro sampling toxicokinetics (PMS-TK) in common marmosets.
Authors: Mochizuki H, Murota N, Sato SI, Nii K, Kouhei Y, Taniguchi M, Inoue R, Nishime C, Tsutsumi H Abstract We investigated the viability of a combined repeated dose toxicity study, including toxicokinetics (TK), in common marmosets according to the ICH-S4, ICH-S3A and ICH-S7A Guidelines using valsartan as test article whose non-clinical repeated dose toxicity studies had been conducted using this species for regulatory purpose. Valsartan was administered orally to 3 animals/sex at 200 mg/kg/day for 2 weeks. In addition to the routine parameters in repeated dose toxicity studies, safety pharmacology parameters (...
Source: Journal of Toxicological Sciences - November 9, 2018 Category: Toxicology Tags: J Toxicol Sci Source Type: research

Sacubitril/valsartan therapeutic strategy in HFpEF: Clinical insights and perspectives
Sacubitril/valsartan represents the first of a new class of drugs able to act as a neprilysin inhibitor and as an angiotensin receptor blocker. This double inhibition has the advantage of concomitantly blocking a pro-fibrotic/pro-hypertrophic mechanism (angiotensin receptor blocker component) while stimulating an anti-fibrotic/anti-hypertrophic mechanism (neprilysin inhibitor component). Furthermore, the novel drug has natriuretic and diuretic properties, better preserves renal function, provides better blood pressure control as compared to renin angiotensin system inhibitors, and improves ventricular-arterial coupling. (S...
Source: International Journal of Cardiology - November 9, 2018 Category: Cardiology Authors: Mauro Gori, Emilia D'Elia, Michele Senni Tags: Review Source Type: research

Initiation, Continuation, Switching, and Withdrawal of Heart Failure Medical Therapies During Hospitalization
Publication date: Available online 7 November 2018Source: JACC: Heart FailureAuthor(s): Aditi A. Bhagat, Stephen J. Greene, Muthiah Vaduganathan, Gregg C. Fonarow, Javed ButlerAbstractPatients with worsening heart failure with reduced ejection fraction (HFrEF) spend a large proportion of time in the hospital and other health care facilities. The benefits of guideline-directed medical therapy (GDMT) in the outpatient setting have been shown in large randomized controlled trials. However, the decision to initiate, continue, switch, or withdraw HFrEF medications in the inpatient setting is often based on multiple factors and ...
Source: JACC: Heart Failure - November 8, 2018 Category: Cardiology Source Type: research

Effect of Amlodipine/Valsartan Versus Nebivolol/Valsartan Fixed Dose Combinations on Peripheral and Central Blood Pressure
AbstractIntroductionAlthough hypertensive drugs may have the same effect on peripheral blood pressure, they vary in their effect on central blood pressure and its indices.AimTo evaluate efficacy of fixed-dose combination of amlodipine 10  mg/valsartan 160 mg versus nebivolol 5 mg/valsartan 160 mg in grade 2 or more hypertensive patients assessed by peripheral and central blood pressure.MethodsA prospective, open label, randomized study done in the outpatient cardiology clinic at Beni-Suef University Hospital. A total of 137 patients continued the study; group I (n  = 75) received Amlodipin...
Source: High Blood Pressure and Cardiovascular Prevention - November 3, 2018 Category: Cardiology Source Type: research

Upstream therapeutic strategies of Valsartan and Fluvastatin on Hypertensive patients with non ‐permanent Atrial Fibrillation (VF‐HT‐AF)
Cardiovascular Therapeutics,Volume 0, Issue ja, -Not available-. (Source: Cardiovascular Therapeutics)
Source: Cardiovascular Therapeutics - November 3, 2018 Category: Cardiology Authors: Zhao Zhiqiang, Xiaowei Niu, ZhaoJie Dong, Wenwei Qi, Enzhao Liu, Tong Liu, Lifeng Li, Yingzi Liang, Guangping Li Source Type: research

Sacubitril/Valsartan-Associated Small Bowel Ileus
No abstract available (Source: American Journal of Therapeutics)
Source: American Journal of Therapeutics - November 1, 2018 Category: Drugs & Pharmacology Tags: Letters to the Editor Source Type: research

Improving access to novel heart failure agents through a defined multidisciplinary pathway
Novel emerging heart failure medication therapies, particularly sacubitril/valsartan and corlanor, have shown promise in improving patient outcomes and decreasing hospitalizations and death in our heart failure population. Patient access and prescription coverage for these novel heart failure medication therapies can be a huge barrier for allowing heart failure patients to have access to these new medications. Recognizing this barrier, our medical center has developed a multidisciplinary pathway to help guide our institution in helping enable our patients to having access to the most cutting edge guideline-directed medical...
Source: Heart and Lung - November 1, 2018 Category: Intensive Care Authors: Mary Chalton Source Type: research

Single-Stranded DNA-Binding Protein 1 Abrogates Cardiac Fibroblast Proliferation and Collagen Expression Induced by Angiotensin II.
In this study, we aim to investigate the role of SSBP1 in cardiac fibrosis that is induced by Ang II. We infused C57BL/6J mice with vehicle or Ang II and valsartan using implanted osmotic mini-pumps. Moreover, heart function was examined by echocardiography and cardiac fibrosis was analyzed via picrosirus red staining. The expression of COL1A1, COL3A1, SSBP1, p53, Nox1, and Nox4 was analyzed via qRT-PCR and/or immunoblots. The SSBP1 expression was manipulated via SSBP1 shRNA and pcDNA3.1/SSBP1 plasmids, while the p53 expression was enhanced via AdCMV-p53 infection. The exposure to Ang II increased the mouse heart weight, s...
Source: International Heart Journal - October 31, 2018 Category: Cardiology Tags: Int Heart J Source Type: research

Kardiale Kontraktilit ätsmodulation zur Behandlung der chronischen Herzinsuffizienz
ZusammenfassungDie Pr ävalenz der Herzinsuffizienz liegt weltweit bei 1–2 % der Bevölkerung mit einem Anteil herzinsuffizienter Patienten>70  Jahren von ≥10 %. Neben der Behandlung kausaler Faktoren und Lifestyle-Modifikationen beruht die Basistherapie der Herzinsuffizienz auf der leitliniengerechten medikamentösen Behandlung mit Angiotensin-Converting-Enzyme-Inhibitoren (ACE-Hemmer), β‑Blockern (BB) und Mineralkortikoid-Rezepto rantagonisten (MRA). Zusätzlich werden Diuretika, Angiotensin-Rezeptorblocker (ARB), Iƒ-Kanal-Blocker und mit einer Klasse-IIb-Empfehlung Digita...
Source: Herzschrittmachertherapie und Elektrophysiologie - October 25, 2018 Category: Cardiology Source Type: research

A New Approach for Hypertension: the Case of Sacubitril/Valsartan Experienced in Randomized Controlled Trials That Selectively Restrict Its Use to the Hypertension of the Elderly.
PMID: 30344822 [PubMed] (Source: Clin Med Res)
Source: Clin Med Res - October 24, 2018 Category: Research Authors: De Vecchis R, Ariano C, Soreca S Tags: J Clin Med Res Source Type: research

Potential Uses of Sacubitril/Valsartan: Need for Data on Efficacy and Safety
AbstractAngiotensin-converting enzyme inhibitors and angiotensin receptor blockers have been the cornerstone for the treatment of heart failure (HF) with reduced ejection fraction for decades. According to recent and promising studies, sacubitril/valsartan (SV) might be efficient in alternative indications in the area of HF with preserved left ventricular ejection fraction, chronic kidney disease, and so on. This review briefly summarizes these promising therapeutic options regarding SV and the potential limits and pitfalls for its use in routine practice (due to cognitive uncertainties). (Source: American Journal of Cardiovascular Drugs)
Source: American Journal of Cardiovascular Drugs - October 22, 2018 Category: Cardiology Source Type: research

A Novel Paradigm For Sacubitril/Valsartan: Beta-Endorphin Elevation As A Contributor To Exercise Tolerance Improvement In Rats With Preexisting Heart Failure Induced By Pressure-Overload
: Simultaneous angiotensin receptor (AT1) blockade and neprilysin inhibition with sacubitril/valsartan has been recently approved to treat patients with heart failure (HF). Therapeutic benefits of this therapy have been attributed to natriuretic peptide elevation and AT1 receptor blockade. However, this pharmacologic picture may not be complete. The aims of this study were to investigate the pharmacology of sacubitril/valsartan in comparison to monotherapies with sacubitril, and valsartan, and to examine their impact on peptides upregulated by neprilysin inhibition, such as beta-endorphin. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - October 19, 2018 Category: Cardiology Authors: MY Maslov, S Foianini, MV Orlov, JL Januzzi, MA Lovich Source Type: research

Troponin ‐I levels as a potential prognostic biomarker of sacubitril/valsartan treatment response in heart failure with reduced ejection fraction: Who will benefit most?
Clinical Cardiology,Volume 0, Issue ja, -Not available-. (Source: Clinical Cardiology)
Source: Clinical Cardiology - October 16, 2018 Category: Cardiology Authors: Eleni S. Nakou, Maria E. Marketou, Gregory I. Chlouverakis, Alexandros P. Patrianakos, Panos E. Vardas, Fragiskos I. Parthenakis Source Type: research

Angiotensin II type 1 receptor blockers prevent aortic arterial stiffness in elderly patients with hypertension.
CONCLUSION: ARB treatment is a negative risk factor of arterial stiffness in aged patients with essential hypertension. PMID: 30311805 [PubMed - as supplied by publisher] (Source: Clinical and Experimental Hypertension)
Source: Clinical and Experimental Hypertension - October 12, 2018 Category: Cardiology Authors: Zhu ML, Sun RL, Zhang HY, Zhao FR, Pan GP, Zhang C, Song P, Li P, Xu J, Wang S, Yin YL Tags: Clin Exp Hypertens Source Type: research

Reply: Sacubitril/valsartan for Chagas' heart disease heart failure?
ESC Heart Failure, EarlyView. (Source: ESC Heart Failure)
Source: ESC Heart Failure - October 9, 2018 Category: Cardiology Authors: Edimar Alcides Bocchi, Salvador Rassi, Guilherme Veiga Guimar ães, Argentine, Chile, and Brazil SHIFT Investigators Source Type: research

Losartan, but not Enalapril and Valsartan, Inhibits the Expression of IFN- γ, IL-6, IL-17F and IL-22 in PBMCs from Rheumatoid Arthritis Patients.
Losartan, but not Enalapril and Valsartan, Inhibits the Expression of IFN-γ, IL-6, IL-17F and IL-22 in PBMCs from Rheumatoid Arthritis Patients. Open Rheumatol J. 2018;12:160-170 Authors: Cardoso PRG, Matias KA, Dantas AT, Marques CDL, Pereira MC, Duarte ALBP, Rego MJBM, Pitta IDR, Pitta MGDR Abstract Background: Rheumatoid Arthritis (RA) is a chronic and inflammatory disease that affects about 1% of the world's population. Almost 70% of RA patients have a cardiovascular disease such as Systemic Arterial Hypertension (SAH). Inflammatory cytokines are clearly involved in the pathogenesis of RA and...
Source: Open Rheumatology Journal - October 7, 2018 Category: Rheumatology Tags: Open Rheumatol J Source Type: research

Recall of N-Nitrosodimethylamine–Contaminated Pseudogeneric Valsartan: Best Generics Finally No Better Than Others?
Publication date: October 2018Source: Canadian Journal of Cardiology, Volume 34, Issue 10Author(s): Jacinthe Leclerc (Source: Canadian Journal of Cardiology)
Source: Canadian Journal of Cardiology - October 4, 2018 Category: Cardiology Source Type: research

Improving Arterial Wall Characteristics in Patients After Myocardial Infarction with a Very Low Dose of Fluvastatin and Valsartan: A Proof-of-Concept Study.
Authors: Turk Veselič M, Eržen B, Hanžel J, Piletič Ž, Šabovič M Abstract BACKGROUND We tested the concept of improving arterial wall characteristics by treatment with a very low-dose combination of fluvastatin and valsartan (low-flu/val) in stable, post-myocardial infarction (MI) patients. MATERIAL AND METHODS We enrolled 36 post-MI middle-aged males in the treatment (n=20) or control (n=16) group receiving low-flu/val (10 mg/20 mg) or placebo, respectively. The parameters of endothelial function (flow-mediated dilatation (FMD), reactive hyperemia index), and arterial stiffness (carotid-femoral pulse ...
Source: Medical Science Monitor - October 1, 2018 Category: Research Tags: Med Sci Monit Source Type: research

Correction to: Do Limitations in the Design of PARADIGM-HF Justify the Slow Real World Uptake of Sacubitril/Valsartan (Entresto)?
The original version of this article unfortunately contained a mistake. There was a typo in the second sentence of the paragraph under the section Was the Dose of Drugs Fair?;"320 mg twice a day" should read"160mg twice a day". The corrected paragraph is shown below. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - October 1, 2018 Category: Cardiology Source Type: research

Cost-Effectiveness Analysis of Sacubitril-Valsartan Compared with Enalapril in Patients with Heart Failure with Reduced Ejection Fraction in Thailand
ConclusionsAt its current price in Thailand, sacubitril-valsartan may not represent good value for the nations ’s limited healthcare resources. The cost of sacubitril-valsartan needs to reduce by approximately 2% to yield an ICER below the threshold. (Source: American Journal of Cardiovascular Drugs)
Source: American Journal of Cardiovascular Drugs - October 1, 2018 Category: Cardiology Source Type: research

Stable but Progressive Nature of Heart Failure: Considerations for Primary Care Physicians
This article provides an overview of the progressive nature of HF in apparently stable patients and describes areas for treatment improvement that may help to optimize patient care. (Source: American Journal of Cardiovascular Drugs)
Source: American Journal of Cardiovascular Drugs - October 1, 2018 Category: Cardiology Source Type: research

Sacubitril/Valsartan (LCZ696): A Novel Treatment for Heart Failure and its Estimated Cost Effectiveness, Budget Impact, and Disease Burden Reduction in Germany
ConclusionsThe ICER of sacubitril/valsartan is projected to be at or below the level of other accepted interventions for the treatment of asymptomatic to severe heart failure in Germany. Projected budget impact leads to an increase in SHI expenditures by  
Source: PharmacoEconomics - October 1, 2018 Category: Health Management Source Type: research

Correction to: Do Limitations in the Design of PARADIGM-HF Justify the Slow Real World Uptake of Sacubitril/Valsartan (Entresto)?
The original version of this article unfortunately contained a mistake. There was a typo in the second sentence of the paragraph under the section Was the Dose of Drugs Fair?;"320 mg twice a day" should read"160mg twice a day". The corrected paragraph is shown below. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - October 1, 2018 Category: Cardiology Source Type: research

Reply: RE: Cost-effectiveness of sacubitril/valsartan versus enalapril in patients with heart failure and reduced ejection fraction.
Authors: Lin L, Bin-Chia Wu D, Aziz MIA, Wong R, Sim D, Leong KTG, Wei YQ, Tan D, Ng K PMID: 30255725 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - September 27, 2018 Category: Health Management Tags: J Med Econ Source Type: research

Intraoperative angioedema induced by angiotensin II receptor blocker: a case report.
Conclusion: The precise mechanism of angiotensin II receptor blocker-induced angioedema is still unknown and should be thoroughly investigated. This report demonstrates a unique case of intraoperative angiotensin II receptor blocker-induced angioedema. Potential differential diagnoses of postoperative facial edema are discussed in detail, including the prolonged prone positioning for posterior spine surgery. Anesthesiologists should be aware of such rare, but potentially dangerous, perioperative adverse reaction that can occur with angiotensin II receptor blockers use. PMID: 30250510 [PubMed] (Source: Patient Safety in Surgery)
Source: Patient Safety in Surgery - September 27, 2018 Category: Surgery Authors: Alhowary AA, Odat H, Alali O, Al-Omari A Tags: Patient Saf Surg Source Type: research

[ASAP] Trans and Cis Conformations of the Antihypertensive Drug Valsartan Respectively Lock the Inactive and Active-like States of Angiotensin II Type 1 Receptor: A Molecular Dynamics Study
Journal of Chemical Information and ModelingDOI: 10.1021/acs.jcim.8b00364 (Source: Journal of Chemical Information and Modeling)
Source: Journal of Chemical Information and Modeling - September 27, 2018 Category: Chemistry Authors: Lingyun Wang, Feng Yan Source Type: research